Pain outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving enzalutamide (ENZA) in a real-world setting: PREMISE

by D. Mott, M. Herdman, A. Robinson, B. Rappe, S. Hilman, U. De Giorgi, S. Joniau, R. Bordonaro, S. Mallick, L-M. Dourthe, M. Mira Flores, J. Gumà, H. Payne, M. De Santis, B. Baron, A. Duran, A. Pranzo, A. Serikoff, M. Pavesi
Published 2020-07-01

PREMIUM: A French prospective multicenter observational study of factors impacting on efficacy and compliance to cetuximab treatment in first-line KRAS wild-type metastatic colorec...

by L Mineur, E François, C Plassot, J M Phelip, L Miglianico, L M Dourthe, N Bonichon, L Moreau, R Guimbaud, D Smith, E Achille, R Hervé, J M Bons, S Remy, R Faroux, A L Villing, A Mahamat, I Rabbia, P Soulié, I Baumgaertner, N Mathé, L Vazquez, R Boustany
Published 2020-01-01